Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 7/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23808976 | 0.86 | ALDH1A1 (0.41) | SIGMAR1LMNAKDM4EALDH1A1HTT | |
| SCHEMBL23809035 | 0.84 | ALOX15 (0.43) | LMNAKDM4EALDH1A1HTTHPGD | |
| SCHEMBL23809108 | 0.84 | CXCR4 (0.39) | SIGMAR1LMNAKDM4EALDH1A1HTT | |
| SCHEMBL26043540 | 0.80 | LMNA (0.49) | SIGMAR1LMNAKDM4EALDH1A1HTT | |
| SCHEMBL23809134 | 0.79 | HRH3 (0.44) | LMNAALDH1A1TSHRL3MBTL1 | |
| SCHEMBL23809110 | 0.79 | LMNA (0.37) | SIGMAR1LMNAALDH1A1TMEM97 | |
| SCHEMBL26038289 | 0.77 | LMNA (0.43) | SIGMAR1LMNAKDM4EALDH1A1HTT | |
| SCHEMBL23809138 | 0.76 | ALDH1A1 (0.40) | KDM4EALDH1A1HTTMAPK1 | |
| SCHEMBL15429567 | 0.76 | SIGMAR1 (0.42) | SIGMAR1LMNAKDM4EALDH1A1HTT | |
| SCHEMBL23809104 | 0.75 | NPSR1 (0.38) | SIGMAR1KDM4EALDH1A1HTTTMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | SIGMAR1 2832/4885LMNA 3021/4885KDM4E 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.